Mesa Laboratories, Inc. (MLAB) Stock Score, Valuation & Financial Research
Mesa Laboratories, Inc. is in the Healthcare sector and Medical - Specialties industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for MLAB
Mesa Laboratories, Inc. currently has a Wall Street Score of 26/100. The stored market price is $120.87. Its financial score is 22/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Mesa Laboratories, Inc. does
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping a
MLAB financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $120.87
- Market capitalization:
- $676.4M
- Revenue:
- $249.1M
- Net income:
- $6.7M
- Free cash flow:
- $39.6M
- Cash:
- $26.9M
- Total debt:
- $155.2M
- EPS:
- 1.22
- P/E ratio:
- 99.1x
- Financial score:
- 22/100
- Valuation score:
- 0/100
- Revenue score:
- 13/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $39.6M, showing positive cash generation.
- The balance sheet shows $26.9M of cash versus $155.2M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MLAB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.